Domov › Množni mielom › Michigan › Detroit
Klinične študije za Množni mielom v Detroit, MI
19 študij za Množni mielom išče udeležence na lokacijah v Detroit in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 3
- Karmanos Cancer Institute, Detroit
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Vključevanje udeležencevFaza 3
- Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Vključevanje udeležencevFaza 3
- Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Vključevanje udeležencevFaza 4
- Barbara Ann Karmanos Cancer Institute, Detroit
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Vključevanje udeležencevFaza 2
- Henry Ford Health Saint John Hospital, Detroit
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Vključevanje udeležencevFaza 3
- Henry Ford Health System, Detroit
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Vključevanje udeležencevFaza 3
- Henry Ford Health Saint John Hospital, Detroit
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Vključevanje udeležencevFaza 1/2
- Karmanos Cancer Institute, Detroit
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Vključevanje udeležencevFaza 1/2
- Research Site, Detroit
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Vključevanje udeležencevFaza 3
- Research Site, Detroit
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Vključevanje udeležencevFaza 2
- Karmanos Cancer Institute, Detroit
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Vključevanje udeležencevFaza 1
- Karmanos Cancer Institute, Detroit
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Vključevanje udeležencevFaza 4
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Vključevanje udeležencevFaza 2
- Karmanos Cancer Institute, Detroit
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Vključevanje udeležencevFaza 3
- Ascension Saint John Hospital, Detroit
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- Karmanos Cancer Institute, Detroit
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Vključevanje udeležencevFaza 1/2
- Karmanos Cancer Institute, Detroit
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Vključevanje udeležencevFaza 3
- GSK Investigational Site, Detroit
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Vključevanje udeležencev
- Karmanos Cancer Institute, Detroit
Študije za Množni mielom v drugih mestih
- New York City, NY60 študij
- Boston, MA42 študij
- Atlanta, GA41 študij
- Houston, TX38 študij
- Durham, NC37 študij
- Nashville, TN32 študij
- Denver, CO27 študij
- Rochester, MN24 študij
- St. Louis, MO24 študij
- Columbus, OH24 študij
- Baldwin Park, CA23 študij
- Chicago, IL22 študij
Druge študije v Detroit
- Nemalicelični pljučni rak44 študij
- Rak dojke33 študij
- Rak (vse vrste)29 študij
- Kolorektalni rak26 študij
- Rak jajčnikov26 študij
- Metastatski rak24 študij
- Rak prostate22 študij
- Rak endometrija21 študij
- Rak pljuč20 študij
- Rak želodca16 študij
- Ploščatocelični karcinom glave in vratu15 študij
- Akutna mieločna levkemija14 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.